Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

NCT03879876 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Pediatric Patients
Any Type of Severe Combined Immunodeficiency (SCID)
Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Interventions

DRUG: Human T Lymphoid Progenitor (HTLP) injection

Sponsor

Assistance Publique - Hôpitaux de Paris